References in periodicals archive ?
Importantly, there were no differences in heart failure medications in both groups with LVRR present or absent, neither at baseline nor at the 12-month follow-up.
In this study, we evaluated the utility of Gal-3 to predict LVRR in patients with RODCM.
Gal-3 has also been associated with outcome and LVRR in patients with valvular heart disease.
This study was of similar design albeit slightly smaller than ours; it used the same definitions for LVRR, but was based on serial cardiac magnetic resonance (CMR) tomography.
The current study demonstrated that Gal-3 levels are associated with LVRR. Cardiac remodeling represents a compensatory mechanism after an initial myocardial insult, leading to left ventricular dysfunction and ultimately heart failure .
However, there were no differences in MRA treatment in both groups (with LVRR present or absent), neither at baseline nor at follow-up.
Acronyms browser ?
Full browser ?